Search Medical Condition
Please enter condition
Please choose location

Edith Cavell Hospital, United Kingdom Clinical Trials

A listing of Edith Cavell Hospital, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Noctura400 Treatment for Diabetic Retinopathy (CANDLE)

Diabetes is regarded by the World Health Organisation (WHO) as a global epidemic, with the global diabetic population anticipated to exceed 500 million by 2020. In the UK there are over 3.5 million people who have diabetes with a growth rate exceeding 150,000 people per year. Diabetic Retinopathy (DR) is ...

Phase N/A

0.0 miles

Learn More »

Global Multicentre Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

This is a multicenter long-term (up to five years post-conversion), non-interventional registry in kidney transplant patients who have been converted from tacrolimus BD to Advagraf. Centers that are providing medical care for kidney transplant patients who may convert patients from tacrolimus BD to Advagraf will be identified and requested to ...

Phase N/A

0.03 miles

Learn More »

International Breast Cancer Biomarker Standard of Care and Real World Outcomes Study

Background/Rationale: Within the setting of metastatic human epidermal growth factor receptor 2 negative (HER2-ve) breast cancer limited epidemiological data exist on the prevalence of pathogenic mutations of breast cancer susceptibility gene (BRCA) and other homologous recombination repair (HRR) genes. There are also limited data on the treatments and clinical outcomes ...

Phase N/A

0.03 miles

Learn More »

Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

OBJECTIVES: Primary - Compare the efficacy and toxicity of single-agent irinotecan hydrochloride (Ir) vs Ir with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal cancer. - Compare the efficacy of single-agent Ir vs Ir with panitumumab (IrP) in these patients. Secondary - Correlate the toxicity of Ir and/or IrC with ...

Phase

1.25 miles

Learn More »

Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

OBJECTIVES: - Identify cancer patients who are low-risk inpatients and meet criteria for early discharge (i.e., symptomatic improvement and temperature ≤ 37.8°C) after receiving oral antibiotics for febrile neutropenia. OUTLINE: This is a randomized, prospective, multicenter study. Patients are stratified by disease type (lymphoma vs solid tumor), duration of registration ...

Phase

1.25 miles

Learn More »

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

OBJECTIVES: Primary - Determine disease-free survival of women with HER2-positive early breast cancer treated with neoadjuvant or adjuvant trastuzumab (Herceptin®) for 6 months versus 12 months. Secondary - Determine the overall survival of patients treated with these regimens. - Determine the expected incremental cost effectiveness (cost per quality adjusted life ...

Phase

1.25 miles

Learn More »

Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A randomized, international, multi-center, double-blinded study in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, pertuzumab and T-DM1. Patients will be randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. Stratification ...

Phase

1.25 miles

Learn More »